author-photo

Xia Han

Novartis

14

Papers

437

Citations

Citation Trend

Filter By

Papers (12) Sort By

Journal Conference Others

Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study.

2021 Lancet Oncology
Show All
- Source
- Cite
- Save
Citations (4)
Safety and efficacy of tisagenlecleucel (tisa-cel) plus pembrolizumab (pembro) in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL): Updated analysis of the phase 1b PORTIA study.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
SAFETY AND EFFICACY OF TISAGENLECLEUCEL PLUS PEMBROLIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA: UPDATED ANALYSIS OF THE PHASE 1B PORTIA STUDY

2021 Hematological Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Myc Expression and Tumor-Infiltrating T Cells Are Associated with Response in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Tisagenlecleucel in the Juliet Trial

2021
Show All
- Source
- Cite
- Save
Citations (0)
Myc Expression and Tumor-Infiltrating T Cells Are Associated with Response in Patients (Pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL) Treated with Tisagenlecleucel in the Juliet Trial

2020 Blood
Show All
- Source
- Cite
- Save
Citations (7)
Correlative Analyses of Patient and Clinical Characteristics Associated with Efficacy in Tisagenlecleucel-Treated Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients in the Juliet Trial

2019 Blood
Show All
- Source
- Cite
- Save
Citations (13)
CORRELATIVE ANALYSES OF CYTOKINE RELEASE SYNDROME AND NEUROLOGICAL EVENTS IN TISAGENLECLEUCEL-TREATED RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS

2019 Hematological Oncology
Show All
- Source
- Cite
- Save
Citations (4)
Correlative Analyses of Cytokine Release Syndrome and Neurological Events in Tisagenlecleucel-Treated Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients

2019 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (3)
PTEN Expression, Not Mutation Status for TSC1, TSC2 or mTOR, Correlates With Outcome on Everolimus in Patients With Renal Cell Carcinoma Treated on RECORD-3

2018 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (20)
Tumor genomic analysis for 128 renal cell carcinoma (RCC) patients receiving first-line everolimus: Correlation between outcome and mutations status in MTOR, TSC1, and TSC2.

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (5)